Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Paclitaxel
Pelareorep · 1 trial · 1 indication
DLTs are defined as study drug-related toxicities graded using Common Terminology Criteria for Adverse events of the National Cancer Institute (NCI CTCAE) V5.0 occurring during DLT period (the first 4 weeks of AN0025 administration in combination with dCRT)
| Arm | Type | Description |
|---|---|---|
| Patients With Advanced or Metastatic Breast Cancer | EXPERIMENTAL | Patients will receive Pelareorep with Paclitaxel for 8 cycles (28 days/cycle). |
| Name | Type | Description |
|---|---|---|
| Pelareorep | DRUG | Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle |
Inclusion Criteria: Subjects are eligible to be included in the study only if all of the following criteria apply: 1. Voluntarily participating in this trial and having signed the Informed Consent Form (ICF). 2. Women aged ≥18 and ≤70 years (at the time of signing ICF). 3. Pathohistologically or c...
Top 20 of 87 competitors
Pelareorep is an investigational small molecule being studied for the treatment of advanced or metastatic breast cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Pelareorep is being developed by Adlai Nortye Ltd., a biopharmaceutical company whose American Depositary Shares trade under the ticker symbol ANL.
Pelareorep is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial has been completed in patients with advanced or metastatic breast cancer.
Pelareorep has one completed Phase 1 clinical trial, NCT05519059, which studied Pelareorep and paclitaxel injection in Chinese patients with advanced or metastatic breast cancer. The trial enrolled 15 female patients aged 18 years and older.
No, Pelareorep is not the same as paclitaxel. Pelareorep is the investigational drug being studied, while paclitaxel is a chemotherapy agent used in combination with Pelareorep in the clinical trial NCT05519059.